CompletedNCT02059642
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Medication studyAges 18–55Israel + United States
Understand this study
What did researchers investigate?
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Gainesville, United States · South Miami, United States and 18 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateMarch 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 300
- Sponsor
- Alcobra Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, Israel
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02059642
- Official title
Show the full official title
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedGainesville, United States · South Miami, United States · Libertyville, United States
17 more locations
- Overland Park, United States
- Lexington, United States
- Boston, United States
- Rochester Hills, United States
- Troy, United States
- Saint Charles, United States
- Las Vegas, United States
- Mount Kisco, United States
- Durham, United States
- Raleigh, United States
- Media, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Herndon, United States
- Haifa, Israel
- Petah Tikva, Israel
Questions about this study
What did researchers investigate?
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
Who is behind this study?
The study sponsor is Alcobra Ltd.
Did this study involve medication?
Yes. The study involved medication, including MG01CI (1400 mg) and placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD